About eagle pharmaceuticals inc. - EGRX
Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. Its products include RYANODEX, BENDEKA and BELRAPZO. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.
EGRX At a Glance
Eagle Pharmaceuticals, Inc.
50 Tice Boulevard
Woodcliff Lake, New Jersey 07677-9991
| Phone | 1-201-326-5300 | Revenue | 316.61M | |
| Industry | Pharmaceuticals: Major | Net Income | 35.64M | |
| Sector | Health Technology | 2022 Sales Growth | 84.563% | |
| Fiscal Year-end | 12 / 2023 | Employees | 135 | |
| View SEC Filings |
EGRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 10.715 |
| Price to Sales Ratio | 1.206 |
| Price to Book Ratio | 1.629 |
| Price to Cash Flow Ratio | 7.53 |
| Enterprise Value to EBITDA | 3.67 |
| Enterprise Value to Sales | 1.238 |
| Total Debt to Enterprise Value | 0.167 |
EGRX Efficiency
| Revenue/Employee | 2,345,259.259 |
| Income Per Employee | 264,014.815 |
| Receivables Turnover | 4.311 |
| Total Asset Turnover | 0.957 |
EGRX Liquidity
| Current Ratio | 1.699 |
| Quick Ratio | 1.22 |
| Cash Ratio | 0.498 |
EGRX Profitability
| Gross Margin | 69.811 |
| Operating Margin | 29.551 |
| Pretax Margin | 19.403 |
| Net Margin | 11.257 |
| Return on Assets | 10.774 |
| Return on Equity | 17.386 |
| Return on Total Capital | 11.918 |
| Return on Invested Capital | 15.146 |
EGRX Capital Structure
| Total Debt to Total Equity | 28.048 |
| Total Debt to Total Capital | 21.904 |
| Total Debt to Total Assets | 16.129 |
| Long-Term Debt to Equity | 24.715 |
| Long-Term Debt to Total Capital | 19.301 |